[
  {
    "ts": "2026-02-13T05:36:38+00:00",
    "headline": "The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call",
    "summary": "Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment",
    "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053638140.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "0556a31a-97db-34e6-9771-2ba435b0b30a",
      "content": {
        "id": "0556a31a-97db-34e6-9771-2ba435b0b30a",
        "contentType": "STORY",
        "title": "The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call",
        "description": "",
        "summary": "Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales. Management attributed performance to robust growth in its newer product portfolio, particularly Lekembi, Skyclaris, Xerxuve, and Calcadi, which collectively surpassed $1 billion in annual revenue. CEO Christopher Viehbacher pointed to successful expansion of VUMERITY within the multiple sclerosis segment",
        "pubDate": "2026-02-13T05:36:38Z",
        "displayTime": "2026-02-13T05:36:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BIIB Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RI16PwyrPkPhFQpSFVHcpw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IR.mhpWSH09RyIH1vck_EQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/3e9471166a0d4ee8c41ab9eef8ac261c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053638140.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-most-interesting-analyst-questions-053638140.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T11:23:22+00:00",
    "headline": "Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture",
    "summary": "Soft earnings didn't appear to concern Biogen Inc.'s ( NASDAQ:BIIB ) shareholders over the last week. We did some...",
    "url": "https://finance.yahoo.com/news/biogens-nasdaq-biib-soft-earnings-112322087.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "55fe89ff-1dda-30a7-b3a7-5b2b682e21b7",
      "content": {
        "id": "55fe89ff-1dda-30a7-b3a7-5b2b682e21b7",
        "contentType": "STORY",
        "title": "Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture",
        "description": "",
        "summary": "Soft earnings didn't appear to concern Biogen Inc.'s ( NASDAQ:BIIB ) shareholders over the last week. We did some...",
        "pubDate": "2026-02-13T11:23:22Z",
        "displayTime": "2026-02-13T11:23:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogens-nasdaq-biib-soft-earnings-112322087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogens-nasdaq-biib-soft-earnings-112322087.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:27:55+00:00",
    "headline": "Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans",
    "summary": "Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts for its lead complement inhibitor program and provide updated timing on pipeline plans, while also emphasizing what they see as potential competitive advantages in neuromuscula",
    "url": "https://www.marketbeat.com/instant-alerts/dianthus-therapeutics-conference-dnth-eyes-q2-2026-cidp-phase-3-interim-readout-expands-pipeline-plans-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "af3dd98e-d052-3361-b1a4-0456502fede7",
      "content": {
        "id": "af3dd98e-d052-3361-b1a4-0456502fede7",
        "contentType": "STORY",
        "title": "Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans",
        "description": "",
        "summary": "Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts for its lead complement inhibitor program and provide updated timing on pipeline plans, while also emphasizing what they see as potential competitive advantages in neuromuscula",
        "pubDate": "2026-02-13T15:27:55Z",
        "displayTime": "2026-02-13T15:27:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/3a7d9de1507b2bb93c83cd37ecba2c42",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Dianthus Therapeutics logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bOZBJUmoR9_jOll6W6x5SA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/3a7d9de1507b2bb93c83cd37ecba2c42.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x12mntzRkKliOrJEkVp4Eg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/3a7d9de1507b2bb93c83cd37ecba2c42.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/dianthus-therapeutics-conference-dnth-eyes-q2-2026-cidp-phase-3-interim-readout-expands-pipeline-plans-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dianthus-therapeutics-conference-dnth-eyes-152755948.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DNTH"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "9887.HK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:40+00:00",
    "headline": "Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $187 from $178, maintaining a Neutral rating on the shares. The firm told investors that Biogen Inc. (NASDAQ:BIIB) delivered another top-/bottom-line beat in its fiscal Q4 […]",
    "url": "https://finance.yahoo.com/news/wedbush-lifts-pt-biogen-inc-145740924.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "65a5626b-5d29-3e51-ae2e-584bcc711c3f",
      "content": {
        "id": "65a5626b-5d29-3e51-ae2e-584bcc711c3f",
        "contentType": "STORY",
        "title": "Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best medical research stocks to buy according to hedge funds. On February 10, Wedbush lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $187 from $178, maintaining a Neutral rating on the shares. The firm told investors that Biogen Inc. (NASDAQ:BIIB) delivered another top-/bottom-line beat in its fiscal Q4 […]",
        "pubDate": "2026-02-13T14:57:40Z",
        "displayTime": "2026-02-13T14:57:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ixRM3d_RV3w5hCozODMpg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIrwEXIPFTzVGiKAPI9LJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wedbush-lifts-pt-biogen-inc-145740924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wedbush-lifts-pt-biogen-inc-145740924.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]